 | • レポートコード：MRC23Q36257 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の患者由来異種移植（PDX）モデル市場について調査・分析し、世界の患者由来異種移植（PDX）モデル市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（マウスモデル、ラットモデル）、用途別セグメント分析（前臨床創薬、バイオマーカー解析）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Crown Bioscience、Champions Oncology、Wuxi Apptec、The Jackson Laboratory、EPO Berlin-Buch、Oncodesign、Xentech、Envigo、Charles River Laboratories、Pharmatest Services、Urosphere、MEDICILON、Horizon Discovery、Shanghai Model Organisms Center、GemPharmatech、LIDE Biotechなどが含まれています。 世界の患者由来異種移植（PDX）モデル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、患者由来異種移植（PDX）モデル市場規模を推定する際に考慮しました。本レポートは、患者由来異種移植（PDX）モデルの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、患者由来異種移植（PDX）モデルに関するビジネス上の意思決定に役立てることを目的としています。 ・患者由来異種移植（PDX）モデル市場の概要 - 患者由来異種移植（PDX）モデルのタイプ別セグメント - 世界の患者由来異種移植（PDX）モデル市場規模：タイプ別分析（マウスモデル、ラットモデル） - 患者由来異種移植（PDX）モデルの用途別セグメント - 世界の患者由来異種移植（PDX）モデル市場規模：用途別分析（前臨床創薬、バイオマーカー解析） - 世界の患者由来異種移植（PDX）モデル市場規模予測（2018年-2029年） ・患者由来異種移植（PDX）モデル市場の成長トレンド - 患者由来異種移植（PDX）モデルの地域別市場規模（2018年-2029年） - 患者由来異種移植（PDX）モデル市場ダイナミクス - 患者由来異種移植（PDX）モデルの業界動向 - 患者由来異種移植（PDX）モデル市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：マウスモデル、ラットモデル - 世界の患者由来異種移植（PDX）モデルのタイプ別市場規模（2018年-2023年） - 世界の患者由来異種移植（PDX）モデルのタイプ別市場規模（2024年-2029年） ・用途別セグメント：前臨床創薬、バイオマーカー解析 - 世界の患者由来異種移植（PDX）モデルの用途別市場規模（2018年-2023年） - 世界の患者由来異種移植（PDX）モデルの用途別市場規模（2024年-2029年） ・患者由来異種移植（PDX）モデルの地域別市場規模 - 北米の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - アメリカの患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - ヨーロッパの患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - アジア太平洋の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - 中国の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - 日本の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - 韓国の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - インドの患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - オーストラリアの患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - 中南米の患者由来異種移植（PDX）モデル市場規模（2018年-2029年） - 中東・アフリカの患者由来異種移植（PDX）モデル市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Crown Bioscience、Champions Oncology、Wuxi Apptec、The Jackson Laboratory、EPO Berlin-Buch、Oncodesign、Xentech、Envigo、Charles River Laboratories、Pharmatest Services、Urosphere、MEDICILON、Horizon Discovery、Shanghai Model Organisms Center、GemPharmatech、LIDE Biotech ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Patient-derived Xenograft (PDX) Models market was valued at US$ 360 million in 2022 and is anticipated to reach US$ 588.6 million by 2029, witnessing a CAGR of 8.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Patient-derived Xenograft (PDX) Models, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient-derived Xenograft (PDX) Models.
The Patient-derived Xenograft (PDX) Models market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Patient-derived Xenograft (PDX) Models market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Patient-derived Xenograft (PDX) Models companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech
Segment by Type
Mouse Model
Rat Model
Segment by Application
Preclinical Drug development
Biomarker Analysis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Patient-derived Xenograft (PDX) Models companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Mouse Model
1.2.3 Rat Model
1.3 Market by Application
1.3.1 Global Patient-derived Xenograft (PDX) Models Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Preclinical Drug development
1.3.3 Biomarker Analysis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Patient-derived Xenograft (PDX) Models Market Perspective (2018-2029)
2.2 Patient-derived Xenograft (PDX) Models Growth Trends by Region
2.2.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Patient-derived Xenograft (PDX) Models Historic Market Size by Region (2018-2023)
2.2.3 Patient-derived Xenograft (PDX) Models Forecasted Market Size by Region (2024-2029)
2.3 Patient-derived Xenograft (PDX) Models Market Dynamics
2.3.1 Patient-derived Xenograft (PDX) Models Industry Trends
2.3.2 Patient-derived Xenograft (PDX) Models Market Drivers
2.3.3 Patient-derived Xenograft (PDX) Models Market Challenges
2.3.4 Patient-derived Xenograft (PDX) Models Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue
3.1.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue (2018-2023)
3.1.2 Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Players (2018-2023)
3.2 Global Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Patient-derived Xenograft (PDX) Models Revenue
3.4 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio
3.4.1 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Patient-derived Xenograft (PDX) Models Revenue in 2022
3.5 Patient-derived Xenograft (PDX) Models Key Players Head office and Area Served
3.6 Key Players Patient-derived Xenograft (PDX) Models Product Solution and Service
3.7 Date of Enter into Patient-derived Xenograft (PDX) Models Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Patient-derived Xenograft (PDX) Models Breakdown Data by Type
4.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Type (2018-2023)
4.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Type (2024-2029)
5 Patient-derived Xenograft (PDX) Models Breakdown Data by Application
5.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Application (2018-2023)
5.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
6.2 North America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
6.4 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
7.2 Europe Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
7.4 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2018-2023)
8.4 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
9.2 Latin America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
9.4 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
10.4 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Crown Bioscience
11.1.1 Crown Bioscience Company Detail
11.1.2 Crown Bioscience Business Overview
11.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Introduction
11.1.4 Crown Bioscience Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.1.5 Crown Bioscience Recent Development
11.2 Champions Oncology
11.2.1 Champions Oncology Company Detail
11.2.2 Champions Oncology Business Overview
11.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Introduction
11.2.4 Champions Oncology Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.2.5 Champions Oncology Recent Development
11.3 Wuxi Apptec
11.3.1 Wuxi Apptec Company Detail
11.3.2 Wuxi Apptec Business Overview
11.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Introduction
11.3.4 Wuxi Apptec Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.3.5 Wuxi Apptec Recent Development
11.4 The Jackson Laboratory
11.4.1 The Jackson Laboratory Company Detail
11.4.2 The Jackson Laboratory Business Overview
11.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Introduction
11.4.4 The Jackson Laboratory Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.4.5 The Jackson Laboratory Recent Development
11.5 EPO Berlin-Buch
11.5.1 EPO Berlin-Buch Company Detail
11.5.2 EPO Berlin-Buch Business Overview
11.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Introduction
11.5.4 EPO Berlin-Buch Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.5.5 EPO Berlin-Buch Recent Development
11.6 Oncodesign
11.6.1 Oncodesign Company Detail
11.6.2 Oncodesign Business Overview
11.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Introduction
11.6.4 Oncodesign Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.6.5 Oncodesign Recent Development
11.7 Xentech
11.7.1 Xentech Company Detail
11.7.2 Xentech Business Overview
11.7.3 Xentech Patient-derived Xenograft (PDX) Models Introduction
11.7.4 Xentech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.7.5 Xentech Recent Development
11.8 Envigo
11.8.1 Envigo Company Detail
11.8.2 Envigo Business Overview
11.8.3 Envigo Patient-derived Xenograft (PDX) Models Introduction
11.8.4 Envigo Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.8.5 Envigo Recent Development
11.9 Charles River Laboratories
11.9.1 Charles River Laboratories Company Detail
11.9.2 Charles River Laboratories Business Overview
11.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Introduction
11.9.4 Charles River Laboratories Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.9.5 Charles River Laboratories Recent Development
11.10 Pharmatest Services
11.10.1 Pharmatest Services Company Detail
11.10.2 Pharmatest Services Business Overview
11.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Introduction
11.10.4 Pharmatest Services Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.10.5 Pharmatest Services Recent Development
11.11 Urosphere
11.11.1 Urosphere Company Detail
11.11.2 Urosphere Business Overview
11.11.3 Urosphere Patient-derived Xenograft (PDX) Models Introduction
11.11.4 Urosphere Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.11.5 Urosphere Recent Development
11.12 MEDICILON
11.12.1 MEDICILON Company Detail
11.12.2 MEDICILON Business Overview
11.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Introduction
11.12.4 MEDICILON Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.12.5 MEDICILON Recent Development
11.13 Horizon Discovery
11.13.1 Horizon Discovery Company Detail
11.13.2 Horizon Discovery Business Overview
11.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Introduction
11.13.4 Horizon Discovery Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.13.5 Horizon Discovery Recent Development
11.14 Shanghai Model Organisms Center
11.14.1 Shanghai Model Organisms Center Company Detail
11.14.2 Shanghai Model Organisms Center Business Overview
11.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Introduction
11.14.4 Shanghai Model Organisms Center Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.14.5 Shanghai Model Organisms Center Recent Development
11.15 GemPharmatech
11.15.1 GemPharmatech Company Detail
11.15.2 GemPharmatech Business Overview
11.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Introduction
11.15.4 GemPharmatech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.15.5 GemPharmatech Recent Development
11.16 LIDE Biotech
11.16.1 LIDE Biotech Company Detail
11.16.2 LIDE Biotech Business Overview
11.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Introduction
11.16.4 LIDE Biotech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.16.5 LIDE Biotech Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details